Indoco Remedies Past Earnings Performance
Past criteria checks 0/6
Indoco Remedies has been growing earnings at an average annual rate of 3.4%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 10.7% per year.
Key information
3.4%
Earnings growth rate
3.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 10.7% |
| Return on equity | -1.3% |
| Net Margin | -0.6% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Recent updates
Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive
Jan 29
₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results
Jan 24Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Oct 27Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders
May 24Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts
Jan 26Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?
Jan 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now
Sep 16Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly
May 21Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Aug 31Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Jul 04Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
Jul 02Indoco Remedies (NSE:INDOCO) Seems To Use Debt Quite Sensibly
Jun 10Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
Mar 25Indoco Remedies Limited's (NSE:INDOCO) Intrinsic Value Is Potentially 21% Below Its Share Price
Mar 09What Percentage Of Indoco Remedies Limited (NSE:INDOCO) Shares Do Insiders Own?
Feb 22Did You Miss Indoco Remedies' (NSE:INDOCO) 37% Share Price Gain?
Feb 07Indoco Remedies Limited's (NSE:INDOCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 17Is Indoco Remedies (NSE:INDOCO) A Risky Investment?
Dec 27
Revenue & Expenses Breakdown
How Indoco Remedies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 17,243 | -107 | 4,761 | 820 |
| 30 Sep 24 | 17,732 | 321 | 4,685 | 875 |
| 30 Jun 24 | 18,223 | 767 | 3,677 | 980 |
| 31 Mar 24 | 18,173 | 985 | 4,621 | 972 |
| 31 Dec 23 | 17,958 | 1,016 | 4,219 | 979 |
| 30 Sep 23 | 17,356 | 1,134 | 4,141 | 936 |
| 30 Jun 23 | 16,869 | 1,281 | 3,307 | 866 |
| 31 Mar 23 | 16,686 | 1,423 | 3,941 | 810 |
| 31 Dec 22 | 16,496 | 1,569 | 3,718 | 766 |
| 30 Sep 22 | 16,084 | 1,617 | 3,616 | 738 |
| 30 Jun 22 | 15,622 | 1,537 | 3,014 | 764 |
| 31 Mar 22 | 15,408 | 1,548 | 3,435 | 746 |
| 31 Dec 21 | 14,368 | 1,393 | 3,407 | 714 |
| 30 Sep 21 | 14,110 | 1,317 | 3,423 | 716 |
| 30 Jun 21 | 13,524 | 1,157 | 2,832 | 660 |
| 31 Mar 21 | 12,415 | 930 | 3,341 | 597 |
| 31 Dec 20 | 12,084 | 734 | 3,372 | 573 |
| 30 Sep 20 | 11,654 | 571 | 3,326 | 529 |
| 30 Jun 20 | 11,298 | 393 | 2,614 | 488 |
| 31 Mar 20 | 11,066 | 241 | 3,167 | 497 |
| 31 Dec 19 | 10,909 | 302 | 2,916 | 488 |
| 30 Sep 19 | 10,640 | 264 | 2,825 | 483 |
| 30 Jun 19 | 10,071 | 111 | 2,767 | 494 |
| 31 Mar 19 | 9,684 | -29 | 2,721 | 515 |
| 31 Mar 18 | 10,424 | 412 | 2,637 | 535 |
| 31 Mar 17 | 10,968 | 771 | 2,605 | 517 |
| 31 Mar 16 | 10,081 | 819 | 2,141 | 432 |
| 31 Mar 15 | 8,570 | 828 | 1,664 | 217 |
| 31 Mar 14 | 7,336 | 580 | 2,616 | 208 |
Quality Earnings: INDOCO is currently unprofitable.
Growing Profit Margin: INDOCO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INDOCO is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare INDOCO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INDOCO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21%).
Return on Equity
High ROE: INDOCO has a negative Return on Equity (-1.34%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 02:08 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indoco Remedies Limited is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| Sarabjit Nangra | Angel Broking Private Limited |
| Srivathsan Ramachandran | Avendus Spark |